What is STATIC and what does it want to achieve?
STATIC is a clinical trial to find out whether people with Chronic Lymphocytic Leukaemia (CLL) who have had a good response to ibrutinib or acalabrutinib can take a break from treatment, and only restart treatment if the CLL comes back
Therefore, we are comparing whether having a break from treatment with ibrutinib or acalabrutinib will work as well as continuing treatment without a break.
We will also test whether taking a break from treatment reduces side effects, whether it lowers the risk of CLL becoming resistant to ibrutinib or acalabrutinib, and whether there is any difference in the overall cost of CLL treatment.
We also want to know whether having a break from ibrutinib or acalabrutinib changes how participants are feeling emotionally, and what they like and do not like about having treatment which includes breaks.